Clinical Trial Update: Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing efficacy and safety of insulin degludec/insulin aspart combination versus BIAsp 30 in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BIAsp-30 (biphasic insulin aspart protamine 30% / insulin aspart 70%)
• insulin degludec/insulin aspart (insulin degludec/insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2018-12-07